Abstract: |
This chapter examines the role of kinase inhibitors in treatment of tumors and cancers. Cancer treatment has seen a new form of treatment in the form of a newer class of "targeted therapies," involving selective kinase inhibitors. In May 2001 imatinib became the first kinase inhibitor approved to treat a human cancer ushering in a new paradigm in cancer drug development. This chapter highlights the clinical applications of kinase inhibitors in the first three specific solid tumors for which kinase inhibitors were approved, gastrointestinal stromal tumor (GISTs), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). In one case (GIST), understanding of the molecular etiology of the disease led to rational drug development; in another case (NSCLC), clinical drug development led to rational dissection of the underlying biology; and in a third case (RCC), an existing body of molecular knowledge provided a framework to begin to understand why a certain class of drugs may be effective. To explain this, the study discusses relevant translational studies. Under this, it touches upon the clinical aspects of these diseases, pharmacologic properties of the kinase inhibitors used in these diseases, and the clinical trial design. The development of such agents has been the direct result of major progress made in the elucidation of molecular signaling events that lead to and sustain cancer. © 2010 Elsevier Inc. All rights reserved. |